Limits...
Prognostic role of LSD1 in various cancers: evidence from a meta-analysis.

Wu J, Hu L, Du Y, Kong F, Pan Y - Onco Targets Ther (2015)

Bottom Line: Eligible studies were identified by searching the online databases PubMed and China National Knowledge Infrastructure up to February 2015.Subgroup analysis by ethnicity, cancer type and HR estimate also showed that high levels of LSD1 were significantly correlated with OS.The meta-analysis showed that LSD1 overexpression may be associated with a worse prognosis in cancer patients.

View Article: PubMed Central - PubMed

Affiliation: The Central Laboratory, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.

ABSTRACT
The prognostic value of lysine-specific demethylase 1 (LSD1) overexpression in various cancers has been investigated by many studies with inconsistent results. A meta-analysis was performed to assess the association between LSD1 and overall survival (OS) in cancer patients. Eligible studies were identified by searching the online databases PubMed and China National Knowledge Infrastructure up to February 2015. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to clarify the correlation between LSD1 expression and prognosis of different cancers. In total, nine studies with 1,149 cancer patients were included for final analysis. The meta-analysis suggested that LSD1 overexpression was associated with poor OS in cancer patients (HR =1.80, 95% CI: 1.39-2.34, P=0.000). Subgroup analysis by ethnicity, cancer type and HR estimate also showed that high levels of LSD1 were significantly correlated with OS. The meta-analysis showed that LSD1 overexpression may be associated with a worse prognosis in cancer patients.

No MeSH data available.


Related in: MedlinePlus

Flowchart of the meta-analysis.Abbreviation: LSD1, lysine-specific demethylase 1.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4592051&req=5

f1-ott-8-2565: Flowchart of the meta-analysis.Abbreviation: LSD1, lysine-specific demethylase 1.

Mentions: The results of the search strategy are described in Figure 1. With our retrieval strategy, a total of 73 references were found. After review of abstracts, we identified 29 potential studies eligible for inclusion in the evaluation. Upon full-text review, nine studies6–14 were selected for our meta-analysis, and the study characteristics are summarized in Table 1. The total number of patients included was 1,149, ranging from 63 to 261 patients per study. Eight studies6–11,13,14 evaluated Asians and one12 evaluated Caucasian. The types of cancers in these studies included esophageal cancer, non-small-cell lung cancer, colon cancer, hepatocellular carcinoma, breast cancer, human melanomas, and tongue cancer. The method of LSD1 detection was based on immunohistochemistry. HRs with 95% CIs were reported directly in five studies,8,10–13 calculated from available data in one study,14 and extrapolated from Kaplan–Meier curves in three studies.6,7,9


Prognostic role of LSD1 in various cancers: evidence from a meta-analysis.

Wu J, Hu L, Du Y, Kong F, Pan Y - Onco Targets Ther (2015)

Flowchart of the meta-analysis.Abbreviation: LSD1, lysine-specific demethylase 1.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4592051&req=5

f1-ott-8-2565: Flowchart of the meta-analysis.Abbreviation: LSD1, lysine-specific demethylase 1.
Mentions: The results of the search strategy are described in Figure 1. With our retrieval strategy, a total of 73 references were found. After review of abstracts, we identified 29 potential studies eligible for inclusion in the evaluation. Upon full-text review, nine studies6–14 were selected for our meta-analysis, and the study characteristics are summarized in Table 1. The total number of patients included was 1,149, ranging from 63 to 261 patients per study. Eight studies6–11,13,14 evaluated Asians and one12 evaluated Caucasian. The types of cancers in these studies included esophageal cancer, non-small-cell lung cancer, colon cancer, hepatocellular carcinoma, breast cancer, human melanomas, and tongue cancer. The method of LSD1 detection was based on immunohistochemistry. HRs with 95% CIs were reported directly in five studies,8,10–13 calculated from available data in one study,14 and extrapolated from Kaplan–Meier curves in three studies.6,7,9

Bottom Line: Eligible studies were identified by searching the online databases PubMed and China National Knowledge Infrastructure up to February 2015.Subgroup analysis by ethnicity, cancer type and HR estimate also showed that high levels of LSD1 were significantly correlated with OS.The meta-analysis showed that LSD1 overexpression may be associated with a worse prognosis in cancer patients.

View Article: PubMed Central - PubMed

Affiliation: The Central Laboratory, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.

ABSTRACT
The prognostic value of lysine-specific demethylase 1 (LSD1) overexpression in various cancers has been investigated by many studies with inconsistent results. A meta-analysis was performed to assess the association between LSD1 and overall survival (OS) in cancer patients. Eligible studies were identified by searching the online databases PubMed and China National Knowledge Infrastructure up to February 2015. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to clarify the correlation between LSD1 expression and prognosis of different cancers. In total, nine studies with 1,149 cancer patients were included for final analysis. The meta-analysis suggested that LSD1 overexpression was associated with poor OS in cancer patients (HR =1.80, 95% CI: 1.39-2.34, P=0.000). Subgroup analysis by ethnicity, cancer type and HR estimate also showed that high levels of LSD1 were significantly correlated with OS. The meta-analysis showed that LSD1 overexpression may be associated with a worse prognosis in cancer patients.

No MeSH data available.


Related in: MedlinePlus